NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,802.40+₹41.40 (+2.35%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
Loading market information…
NSE · REMUS.NS · INR
Stock price, dividends
Quote as of Oct 30, 2026, 05:21 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Remus Pharmaceuticals Ltd.’s quoted price sits in the upper half of its reported 52-week range, 19.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Remus Pharmaceuticals Ltd.’s forward annual dividend is ₹0.50 per share, paid annual. The forward yield is 0.06% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
Remus Pharmaceuticals Ltd. is a pharmaceutical company engaged in the marketing, trading, and distribution of finished dosage formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company's diverse product portfolio, exceeding 600 offerings, includes tablets, capsules, injections, creams, gels, eye drops, and various other dosage forms. Remus Pharmaceuticals focuses on therapeutic categories such as Critical Care, Oncology, Nephrology, Central Nervous System, Cardiology, Diabetics, Antibiotics, Immunosuppressants, Anti-inflammatory, Antifungal, Antipsychotic, Antiretroviral, Dermatology, Urology, and products for vitamin deficiency. The company primarily targets export markets, with significant operations in the Middle East, Africa, Southeast Asia, Latin America, and other emerging global markets. Leveraging an asset-light business model, Remus Pharmaceuticals collaborates with third-party and contract manufacturers, while also possessing manufacturing capabilities in India and the USA, to produce and distribute cost-effective generic alternatives. Additionally, the company provides technical and consultancy services for preparing product dossiers for international registration and engages in research and development for generic drugs and clinical trials.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
KEEP COMPARING
₹1,802.40+₹41.40 (+2.35%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
₹9,745.50+₹81.50 (+0.84%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
₹4,629.40+₹49.40 (+1.08%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 11.82% below the high.
₹2,362.80+₹118.80 (+5.29%)
Laurus Labs Limited’s quoted price sits in the upper half of its reported 52-week range, 0.8% below the high.
₹1,235.00+₹50.60 (+4.27%)
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 1.11% below the high.
₹8,308.00+₹108.00 (+1.32%)
Apollo Hospitals Enterprise Limited’s quoted price sits in the upper half of its reported 52-week range, 8.41% below the high.
₹681.00-₹0.75 (-0.11%)
Lenskart Solutions Limited’s quoted price sits in the upper half of its reported 52-week range, 6.07% below the high.
₹1,355.70+₹10.70 (+0.8%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.18% below the high.
